- Home
- PROK vs ERAS Comparison
PROK vs ERAS Comparison
Compare PROK & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- ERAS
- Stock Information
- Founded
- PROK 2015
- ERAS 2018
- Country
- PROK United States
- ERAS United States
- Employees
- PROK N/A
- ERAS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- ERAS Health Care
- Exchange
- PROK Nasdaq
- ERAS Nasdaq
- Market Cap
- PROK 417.1M
- ERAS 439.7M
- IPO Year
- PROK N/A
- ERAS 2021
- Fundamental
- Price
- PROK $2.78
- ERAS $2.36
- Analyst Decision
- PROK Strong Buy
- ERAS Buy
- Analyst Count
- PROK 4
- ERAS 6
- Target Price
- PROK $6.25
- ERAS $3.67
- AVG Volume (30 Days)
- PROK 1.5M
- ERAS 1.2M
- Earning Date
- PROK 11-10-2025
- ERAS 11-07-2025
- Dividend Yield
- PROK N/A
- ERAS N/A
- EPS Growth
- PROK N/A
- ERAS N/A
- EPS
- PROK N/A
- ERAS N/A
- Revenue
- PROK $744,000.00
- ERAS N/A
- Revenue This Year
- PROK $471.74
- ERAS N/A
- Revenue Next Year
- PROK N/A
- ERAS N/A
- P/E Ratio
- PROK N/A
- ERAS N/A
- Revenue Growth
- PROK N/A
- ERAS N/A
- 52 Week Low
- PROK $0.46
- ERAS $1.01
- 52 Week High
- PROK $7.13
- ERAS $3.30
- Technical
- Relative Strength Index (RSI)
- PROK 45.61
- ERAS 54.04
- Support Level
- PROK $2.56
- ERAS $2.11
- Resistance Level
- PROK $2.94
- ERAS $2.41
- Average True Range (ATR)
- PROK 0.23
- ERAS 0.16
- MACD
- PROK -0.05
- ERAS -0.03
- Stochastic Oscillator
- PROK 25.41
- ERAS 57.47
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.